$KPTI
Karyopharm Therapeutics Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515370974 Filed on November 09, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $25.00K $75.00K $21.00K
YoY Change 56.25% 257.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.260M $4.760M $3.810M
YoY Change -11.15% 24.93% 141.14%
% of Gross Profit
Research & Development $24.06M $25.92M $15.95M
YoY Change 20.06% 62.52% 106.14%
% of Gross Profit
Depreciation & Amortization $170.0K $170.0K $100.0K
YoY Change 30.77% 70.0% 150.0%
% of Gross Profit
Operating Expenses $29.33M $30.69M $19.77M
YoY Change 12.98% 55.25% 112.05%
Operating Profit -$29.30M -$30.61M -$19.74M
YoY Change 12.96% 55.03% 111.82%
Interest Expense $250.0K $240.0K $20.00K
YoY Change 525.0% 1100.0%
% of Operating Profit
Other Income/Expense, Net $257.0K $237.0K $20.00K
YoY Change 1735.71% 1085.0%
Pretax Income -$29.05M -$30.37M -$19.72M
YoY Change 12.03% 54.01% 111.59%
Income Tax
% Of Pretax Income
Net Earnings -$29.05M -$30.37M -$19.72M
YoY Change 12.03% 53.99% 111.63%
Net Earnings / Revenue -116184.0% -40497.33% -93923.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$812.6K -$850.5K -$605.7K
COMMON SHARES
Basic Shares Outstanding 35.73M shares 35.71M shares 32.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $175.6M $195.2M $227.1M
YoY Change -14.63% -14.05% 329.3%
Cash & Equivalents $58.36M $43.50M $227.1M
Short-Term Investments $117.3M $151.7M
Other Short-Term Assets $2.000M $3.100M $4.200M
YoY Change 0.0% -26.19% 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $177.6M $198.3M $231.3M
YoY Change -14.51% -14.27% 331.62%
LONG-TERM ASSETS
Property, Plant & Equipment $3.483M $3.660M $2.734M
YoY Change 26.47% 33.87% 1267.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $33.90M $34.40M
YoY Change 289.66%
Other Assets $500.0K $52.00K $675.0K
YoY Change -35.4% -92.3% -67.86%
Total Long-Term Assets $37.84M $38.63M $3.809M
YoY Change 200.68% 914.1% 65.61%
TOTAL ASSETS
Total Short-Term Assets $177.6M $198.3M $231.3M
Total Long-Term Assets $37.84M $38.63M $3.809M
Total Assets $215.4M $237.0M $235.2M
YoY Change -2.22% 0.77% 320.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.808M $4.568M $2.102M
YoY Change -39.44% 117.32% 23.65%
Accrued Expenses $11.02M $9.469M $3.649M
YoY Change 89.24% 159.5% 92.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.13M $14.44M $6.234M
YoY Change 23.01% 131.63% 55.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.900M $1.900M $1.100M
YoY Change 58.33% 72.73%
Total Long-Term Liabilities $1.900M $1.900M $1.100M
YoY Change 58.33% 72.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.13M $14.44M $6.234M
Total Long-Term Liabilities $1.900M $1.900M $1.100M
Total Liabilities $17.08M $16.38M $7.351M
YoY Change 26.1% 122.81% 83.78%
SHAREHOLDERS EQUITY
Retained Earnings -$256.5M -$227.5M
YoY Change 85.42%
Common Stock $455.2M $448.1M $3.000K
YoY Change 31.87% 14936533.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.4M $220.6M $227.8M
YoY Change
Total Liabilities & Shareholders Equity $215.4M $237.0M $235.2M
YoY Change -2.22% 0.77% 320.67%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$29.05M -$30.37M -$19.72M
YoY Change 12.03% 53.99% 111.63%
Depreciation, Depletion And Amortization $170.0K $170.0K $100.0K
YoY Change 30.77% 70.0% 150.0%
Cash From Operating Activities -$20.38M -$25.33M -$16.23M
YoY Change 59.59% 56.07% 82.36%
INVESTING ACTIVITIES
Capital Expenditures -$510.0K -$140.0K -$2.290M
YoY Change 466.67% -93.89% 7533.33%
Acquisitions
YoY Change
Other Investing Activities $34.35M $44.69M $0.00
YoY Change -153.84%
Cash From Investing Activities $33.85M $44.55M -$2.290M
YoY Change -152.98% -2045.41% 7533.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $112.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.480M 40.00K 113.3M
YoY Change 886.67% -99.96% 156.54%
NET CHANGE
Cash From Operating Activities -20.38M -25.33M -16.23M
Cash From Investing Activities 33.85M 44.55M -2.290M
Cash From Financing Activities 1.480M 40.00K 113.3M
Net Change In Cash 14.95M 19.26M 94.82M
YoY Change -119.54% -79.69% 168.99%
FREE CASH FLOW
Cash From Operating Activities -$20.38M -$25.33M -$16.23M
Capital Expenditures -$510.0K -$140.0K -$2.290M
Free Cash Flow -$19.87M -$25.19M -$13.94M
YoY Change 56.7% 80.7% 57.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3681 sqft
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
374000
CY2014Q4 kpti Operating Lease Scheduled Rent Payments Due
OperatingLeaseScheduledRentPaymentsDue
420000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35732213 shares
CY2014Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
29933 sqft
CY2014Q1 us-gaap Security Deposit
SecurityDeposit
400000
CY2014Q1 kpti Estimated Future Security Deposit
EstimatedFutureSecurityDeposit
200000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227131000
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35711950 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
45 Securities
CY2015Q3 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35711950 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
448095000
CY2015Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
377000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2083000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
220592000
CY2015Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
492000
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
200000
CY2015Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
203000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1939000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
91000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4568000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9469000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227481000
CY2015Q3 us-gaap Liabilities
Liabilities
16379000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
236971000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
951000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14440000
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
186168000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2015Q3 us-gaap Assets
Assets
236971000
CY2015Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
46000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
200398000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3660000
CY2015Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
485000
CY2015Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
78779000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
198344000
CY2015Q3 us-gaap Tenant Improvements
TenantImprovements
568000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3107000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43499000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4611000
CY2015Q3 us-gaap Short Term Investments
ShortTermInvestments
151738000
CY2015Q3 us-gaap Long Term Investments
LongTermInvestments
34430000
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
186123000
CY2015Q3 kpti Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
27701 sqft
CY2015Q3 kpti Additional Area Included In Operating Sublease After Amendment
AdditionalAreaIncludedInOperatingSubleaseAfterAmendment
16234 sqft
CY2015Q3 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
6517000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155974000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32699380 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
11 Securities
CY2014Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
0 Securities
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32699380 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345166000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
309000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1568000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
206794000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
324000
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
126000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1242000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6288000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5825000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138346000
CY2014Q4 us-gaap Liabilities
Liabilities
13543000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220337000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
494000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12301000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
63773000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
774000
CY2014Q4 us-gaap Assets
Assets
220337000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
192982000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2754000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
400000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
12635000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
207751000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2027000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150609000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3248000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
55115000
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
8658000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
63795000
CY2014Q4 kpti Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3624000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38680000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.63
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30619074 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2735000
us-gaap Net Income Loss
NetIncomeLoss
-49849000
us-gaap Sales Revenue Net
SalesRevenueNet
214000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-1259000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2233000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-49903000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
54000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
645000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-50000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
400000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49849000
us-gaap Investment Income Interest
InvestmentIncomeInterest
54000
us-gaap Share Based Compensation
ShareBasedCompensation
9649000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-65000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
349000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
71157000
us-gaap Operating Expenses
OperatingExpenses
50117000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3135000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
112972000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40089000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2601000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
135000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10028000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
362000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
191000
kpti Restricted Shares Common Stock Vested Value
RestrictedSharesCommonStockVestedValue
97000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
112837000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-73654000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.51
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
5403 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
911000
us-gaap Net Income Loss
NetIncomeLoss
-89135000
us-gaap Sales Revenue Net
SalesRevenueNet
225000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-771000
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Trading Symbol
TradingSymbol
KPTI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35575745 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1080000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
125000
us-gaap Operating Income Loss
OperatingIncomeLoss
-89773000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
262474000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
638000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1343000
us-gaap Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
505000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-774000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
85000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
68000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89132000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-65000
us-gaap Investment Income Interest
InvestmentIncomeInterest
647000
us-gaap Share Based Compensation
ShareBasedCompensation
11713000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
763000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-107110000
us-gaap Operating Expenses
OperatingExpenses
89998000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-124666000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
138804000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
91216000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73680000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-6000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3602000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
386000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16318000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2099000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
457000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
52000
kpti Restricted Shares Common Stock Vested Value
RestrictedSharesCommonStockVestedValue
111000
kpti Operating Leases Allowance For Improvements
OperatingLeasesAllowanceForImprovements
1616000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
90830000
CY2014Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2014Q1 kpti Lessee Leasing Arrangements Operating Leases Additional Extension Term
LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm
P5Y
CY2014Q1 kpti Number Of Additional Lease Terms Option To Renew
NumberOfAdditionalLeaseTermsOptionToRenew
1 Lease
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32558646 shares
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-19724000
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
21000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19744000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19724000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
197000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
19765000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15951000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3814000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35708739 shares
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-30373000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
75000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30610000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
237000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
110000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30255000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
239000
CY2015Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
299000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
30685000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25923000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4762000

Files In Submission

Name View Source Status
0001193125-15-370974-index-headers.html Edgar Link pending
0001193125-15-370974-index.html Edgar Link pending
0001193125-15-370974.txt Edgar Link pending
0001193125-15-370974-xbrl.zip Edgar Link pending
d60961d10q.htm Edgar Link pending
d60961dex101.htm Edgar Link pending
d60961dex102.htm Edgar Link pending
d60961dex103.htm Edgar Link pending
d60961dex104.htm Edgar Link pending
d60961dex105.htm Edgar Link pending
d60961dex311.htm Edgar Link pending
d60961dex312.htm Edgar Link pending
d60961dex321.htm Edgar Link pending
d60961dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20150930.xml Edgar Link completed
kpti-20150930.xsd Edgar Link pending
kpti-20150930_cal.xml Edgar Link unprocessable
kpti-20150930_def.xml Edgar Link unprocessable
kpti-20150930_lab.xml Edgar Link unprocessable
kpti-20150930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending